2026 Global: Coronary Intravascular Lithotripsy (Ivl) Market-Competitive Review (2032) report
Description
The 2026 Global: Coronary Intravascular Lithotripsy (Ivl) Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for coronary intravascular lithotripsy (ivl) market by geography and historical trend. The scope of the report extends to sizing of the coronary intravascular lithotripsy (ivl) market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The coronary intravascular lithotripsy (IVL) market features Shockwave Medical (Johnson & Johnson) as the dominant leader, having pioneered the technology with FDA approvals for peripheral artery disease in 2016 and coronary applications in 2021, capturing significant share through devices like the Shockwave C2 Coronary IVL Catheter and Javelin Peripheral IVL Catheter. Boston Scientific challenges this dominance via its $664 million acquisition of Bolt Medical in January 2025, securing FDA-cleared laser-based IVL for coronary and peripheral use, alongside collaborations enhancing its cardiovascular portfolio amid 15-17% growth forecasts for 2025. Medtronic advances with integrated IVL systems for calcified lesions, leveraging its strong interventional cardiology presence in North America, where it holds key market revenue alongside robust R&D. Abbott Laboratories expands aggressively, launching a March 2025 trial for coronary IVL and acquiring Cardiovascular Systems Inc. (CSI) in 2023 for $890 million to integrate CSI's IVL with orbital atherectomy, targeting complex lesions. Philips Healthcare (including Spectranetics) contributes through imaging-guided IVL platforms, supporting precise calcium modification in high-risk coronary procedures.
Cardiovascular Systems, Inc. (CSI, under Abbott) develops proprietary IVL balloons and consoles, completing feasibility testing by 2022 to complement atherectomy tools for undilatable stents and in-stent restenosis. MicroPort Scientific Corporation, via subsidiaries like MicroPort RotaPace and Coronary, gained China approval in February 2024 for the TomaHawk system with real-time pressure monitoring, surpassing 10 million coronary stent shipments by 2025 while rolling out IVL globally. Becton Dickinson (BD), incorporating C.R. Bard, focuses on vessel preparation devices compatible with IVL for calcified coronary artery disease (CAD), driving uptake in North America's 43-79% regional dominance. Terumo Corporation offers specialized IVL catheters for bifurcations and under-expanded stents, benefiting from Asia-Pacific growth in CAD burden. Biotronik SE & Co. KG innovates in bioresorbable and IVL-integrated stents, emphasizing safety in complex lesions amid Europe's rising procedural volumes.
Koninklijke Philips N.V. enhances IVL with advanced imaging for 99% lesion delivery success in registries like REPLICA-EPIC, targeting cardiac cath labs holding 70% end-user share. Emerging players like Elixir Medical launched the CE-marked LithiX Hertz Contact system in April 2025 for energy-free calcium fracturing, while FastWave Medical shares first-in-human data on advanced coronary IVL. The market, valued at hundreds of millions in 2025 and projected to billions by 2034-2035, thrives on CAD's 64.6% application dominance, North America's infrastructure lead, and innovations fracturing calcium via sonic pressure waves for superior stent expansion in 49% undilatable lesions. Competition intensifies as J&J/Shockwave faces Boston, Abbott, and Asian entrants like MicroPort, with clinical endorsements accelerating adoption in hospitals (38.6% distribution channel).
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for coronary intravascular lithotripsy (ivl) market by geography and historical trend. The scope of the report extends to sizing of the coronary intravascular lithotripsy (ivl) market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The coronary intravascular lithotripsy (IVL) market features Shockwave Medical (Johnson & Johnson) as the dominant leader, having pioneered the technology with FDA approvals for peripheral artery disease in 2016 and coronary applications in 2021, capturing significant share through devices like the Shockwave C2 Coronary IVL Catheter and Javelin Peripheral IVL Catheter. Boston Scientific challenges this dominance via its $664 million acquisition of Bolt Medical in January 2025, securing FDA-cleared laser-based IVL for coronary and peripheral use, alongside collaborations enhancing its cardiovascular portfolio amid 15-17% growth forecasts for 2025. Medtronic advances with integrated IVL systems for calcified lesions, leveraging its strong interventional cardiology presence in North America, where it holds key market revenue alongside robust R&D. Abbott Laboratories expands aggressively, launching a March 2025 trial for coronary IVL and acquiring Cardiovascular Systems Inc. (CSI) in 2023 for $890 million to integrate CSI's IVL with orbital atherectomy, targeting complex lesions. Philips Healthcare (including Spectranetics) contributes through imaging-guided IVL platforms, supporting precise calcium modification in high-risk coronary procedures.
Cardiovascular Systems, Inc. (CSI, under Abbott) develops proprietary IVL balloons and consoles, completing feasibility testing by 2022 to complement atherectomy tools for undilatable stents and in-stent restenosis. MicroPort Scientific Corporation, via subsidiaries like MicroPort RotaPace and Coronary, gained China approval in February 2024 for the TomaHawk system with real-time pressure monitoring, surpassing 10 million coronary stent shipments by 2025 while rolling out IVL globally. Becton Dickinson (BD), incorporating C.R. Bard, focuses on vessel preparation devices compatible with IVL for calcified coronary artery disease (CAD), driving uptake in North America's 43-79% regional dominance. Terumo Corporation offers specialized IVL catheters for bifurcations and under-expanded stents, benefiting from Asia-Pacific growth in CAD burden. Biotronik SE & Co. KG innovates in bioresorbable and IVL-integrated stents, emphasizing safety in complex lesions amid Europe's rising procedural volumes.
Koninklijke Philips N.V. enhances IVL with advanced imaging for 99% lesion delivery success in registries like REPLICA-EPIC, targeting cardiac cath labs holding 70% end-user share. Emerging players like Elixir Medical launched the CE-marked LithiX Hertz Contact system in April 2025 for energy-free calcium fracturing, while FastWave Medical shares first-in-human data on advanced coronary IVL. The market, valued at hundreds of millions in 2025 and projected to billions by 2034-2035, thrives on CAD's 64.6% application dominance, North America's infrastructure lead, and innovations fracturing calcium via sonic pressure waves for superior stent expansion in 49% undilatable lesions. Competition intensifies as J&J/Shockwave faces Boston, Abbott, and Asian entrants like MicroPort, with clinical endorsements accelerating adoption in hospitals (38.6% distribution channel).
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.